CTI BioPharma News

1,46 +24,68% +0,289 €
13.12.19 17:53:12 Frankfurt | Orderbuch | Mehr Kurse »
WKN: A2DJWX
ISIN: US12648L6011
US-Symbol: CTIC
Typ: Aktie

CTI BioPharma News

  
Mo CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting PR Newswire
06.11.19 CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting PR Newswire
04.11.19 CTI BioPharma Reports Third Quarter 2019 Financial Results PR Newswire
01.10.19 CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia PR Newswire
01.08.19 CTI BioPharma Reports Second Quarter 2019 Financial Results PR Newswire
18.07.19 CTI BioPharma Announces Outcome From End-​of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis PR Newswire
13.06.19 CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20 PR Newswire
29.05.19 CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5 PR Newswire
02.05.19 CTI BioPharma Reports First Quarter 2019 Financial Results PR Newswire
03.04.19 CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10 PR Newswire
13.03.19 CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights PR Newswire
12.03.19 CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19 PR Newswire
20.02.19 CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27 PR Newswire
11.02.19 CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® PR Newswire
01.02.19 CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update PR Newswire
28.12.18 CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib PR Newswire
18.12.18 CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development PR Newswire
13.12.18 CTI BioPharma Announces Restructuring Plan PR Newswire
26.11.18 CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency PR Newswire
01.11.18 CTI BioPharma Reports Third Quarter 2018 Financial Results PR Newswire
25.10.18 CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018 PR Newswire
01.10.18 CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review PR Newswire
26.09.18 CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3 PR Newswire
02.08.18 CTI BioPharma Reports Second Quarter 2018 Financial Results PR Newswire
26.07.18 CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018 PR Newswire
18.07.18 CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA PR Newswire
09.07.18 Results of Phase III (PIX306) Trial Evaluating Progression-​Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-​Hodgkin Lymphoma PR Newswire
02.07.18 CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib PR Newswire
14.06.18 CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference PR Newswire
06.06.18 CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
03.05.18 CTI BioPharma Reports First Quarter 2018 Financial Results PR Newswire
26.04.18 CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018 PR Newswire
09.03.18 CTI BioPharma to Present at Upcoming Investor Conferences PR Newswire
09.03.18 CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology PR Newswire
07.03.18 CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
28.02.18 CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 PR Newswire
14.02.18 CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference PR Newswire
13.02.18 CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock PR Newswire
09.02.18 CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock PR Newswire
05.02.18 CTI BioPharma Announces Launch of Follow-On Offering PR Newswire
25.01.18 CTI BioPharma Provides Corporate and European Regulatory Update PR Newswire
18.01.18 CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX® PR Newswire
08.11.17 CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
06.11.17 CTI BioPharma Reports Third Quarter 2017 Financial Results PR Newswire
30.10.17 CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017 PR Newswire
26.09.17 CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions PR Newswire
31.08.17 CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference PR Newswire
03.08.17 CTI BioPharma Reports Second Quarter 2017 Financial Results PR Newswire
02.08.17 CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-​Hodgkin lymphoma PR Newswire
01.08.17 CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib PR Newswire

Newssuche